The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes
Open accessAbstract
Importance: Blood-based biomarkers have the potential to improve the identification of persons with the greatest dementia risk for inclusion in dementia prevention trials through low-cost and minimally invasive screening. Objective: To investigate the use of plasma total tau as a blood biomarker for dementia and related endophenotypes. Design, Setting, and Participants: This prospective cohort study used data from the US community-based Framingham Heart Study with replication in the Memento study, a multicenter cohort of persons with mild cognitive impairment or subjective cognitive complaints recruited from memory clinics across France. Total tau levels were measured from stored plasma samples in Framingham Heart Study participants during 2004 to 2011. Dementia follow-up occurred across a median of 6 years (interquartile range, 5-8 years) for persons 65 years and older who were dementia free at baseline. Plasma and/or cerebrospinal fluid samples were obtained from Memento study participants from April 19, 2011, to June 22, 2016. Dementia follow-up took place over a median of 4 years (interquartile range, 3-5 years). Data analysis was performed from January to November 2018. Exposures: Plasma total tau level measured using single-molecule array technology. Main Outcomes and Measures: Incidence of dementia of any cause (all dementia) and dementia due to clinical Alzheimer disease (AD dementia). Results: Among the 1453 participants in the Framingham dementia study sample, the mean (SD) age was 75 (7) years; 792 (54.5%) were female. Among the 367 individuals in the replication cohort, the mean (SD) age was 69 (9) years; 217 (59.1%) were female. Of 134 cases of incident all dementia in the Framingham sample, 105 were AD dementia. After adjustment for age and sex, each SD unit increase in the log of plasma total tau level was associated with a 35% increase in AD dementia risk (hazard ratio [HR], 1.35; 95% CI, 1.10-1.67). The addition of plasma total tau to a model including age and sex improved the stratification of participants for risk of AD dementia (net reclassification improvement, 0.382; 95% CI, 0.030-0.716). Higher plasma total tau level was associated with poorer cognition across 7 cognitive tasks (P < .05) and smaller hippocampi (hippocampal volume: β [SE] = 0.002 [0.001]; P = .003) as well as neurofibrillary tangles (β [SE] = 0.95 [0.45]; P = .04) and microinfarcts (odds ratio, 3.04; 95% CI, 1.26-7.37) at autopsy. In the replication cohort, plasma total tau level weakly correlated with cerebrospinal fluid total tau level (Spearman correlation coefficient, 0.16; P = .07), but plasma total tau was at least as strongly associated with incident AD dementia as cerebrospinal fluid total tau (log plasma total tau: HR, 2.33; 95% CI, 1.00-5.48; log cerebrospinal fluid total tau: HR, 2.14; 95% CI, 1.33-3.44) after adjustment for age and sex. Conclusions and Relevance: The findings suggest that plasma total tau levels may improve the prediction of future dementia, are associated with dementia endophenotypes, and may be used as a biomarker for risk stratification in dementia prevention trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Self-citationTrail Making Test A and B: normative data stratified by age and education
Tombaugh, T. (2004) · Archives of Clinical Neuropsychology · doi:10.1016/s0887-6177(03)00039-8 · Cited by 3,239
Epidemiological approaches to heart disease: the Framingham study
Dawber, T. R., Meadors, G. F., & Moore, F. E. (1951) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.41.3.279 · Cited by 2,148
Rissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1641 · Cited by 2,119
Incidence of dementia over three decades in the Framingham heart study
Satizabal, C. L., Beiser, A. S., Chouraki, V., Chêne, G., Dufouil, C., & Seshadri, S. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504327 · Cited by 1,051
Self-citationDeCarli, C., Massaro, J., Harvey, D., Hald, J., Tullberg, M., Au, R., Beiser, A., D’Agostino, R., & Wolf, P. A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.05.004 · Cited by 680
Self-citation
Research works printed but not linked: 21
- Rissin, 2011, Simultaneous detection of single molecules and singulated ensembles of molecules enables immunoassays with broad dynamic range., Anal Chem, 83, 2279, 10.1021/ac103161b · DOI · Paper page
- Zetterberg, 2013, Plasma tau levels in Alzheimer’s disease., Alzheimers Res Ther, 5, 9, 10.1186/alzrt163 · DOI · Paper page
- Olsson, 2016, CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis., Lancet Neurol, 15, 673, 10.1016/S1474-4422(16)00070-3 · DOI · Paper page
- Dage, 2016, Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort., Alzheimers Dement, 12, 1226, 10.1016/j.jalz.2016.06.001 · DOI · Paper page
- Mielke, 2017, Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic study on aging., JAMA Neurol, 74, 1073, 10.1001/jamaneurol.2017.1359 · DOI · Paper page
- Feinleib, 1975, The Framingham Offspring Study. design and preliminary data., Prev Med, 4, 518, 10.1016/0091-7435(75)90037-7 · DOI · Paper page
- Splansky, 2007, The Third Generation Cohort of the National Heart, Lung, and Blood Institute’s Framingham Heart Study: design, recruitment, and initial examination., Am J Epidemiol, 165, 1328, 10.1093/aje/kwm021 · DOI · Paper page
- McKhann, 1984, Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease., Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
- Ahl, 2013, Defining MCI in the Framingham Heart Study Offspring: education versus WRAT-based norms., Alzheimer Dis Assoc Disord, 27, 330, 10.1097/WAD.0b013e31827bde32 · DOI
- Aljabar, 2009, Multi-atlas based segmentation of brain images: atlas selection and its effect on accuracy., Neuroimage, 46, 726, 10.1016/j.neuroimage.2009.02.018 · DOI · Paper page
- Delacourte, 1999, The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease., Neurology, 52, 1158, 10.1212/WNL.52.6.1158 · DOI · Paper page
- Pencina, 2011, Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers., Stat Med, 30, 11, 10.1002/sim.v30.1 · doi:10.1002/sim.v30.1
- Hosmer, 1995, Confidence interval estimates of an index of quality performance based on logistic regression models., Stat Med, 14, 2161, 10.1002/(ISSN)1097-0258 · DOI
- Pase, 2017, Role of improved vascular health in the declining incidence of dementia., Stroke, 48, 2013, 10.1161/STROKEAHA.117.013369 · DOI
- Dufouil, 2017, Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort., Alzheimers Res Ther, 9, 67, 10.1186/s13195-017-0288-0 · DOI
- Schraen-Maschke, 2008, Tau as a biomarker of neurodegenerative diseases., Biomark Med, 2, 363, 10.2217/17520363.2.4.363 · DOI
- Deters, 2017, Plasma tau association with brain atrophy in mild cognitive impairment and Alzheimer’s disease., J Alzheimers Dis, 58, 1245, 10.3233/JAD-161114 · DOI
- Müller, 2017, Tau plasma levels in subjective cognitive decline: results from the DELCODE study., Sci Rep, 7, 9529, 10.1038/s41598-017-08779-0 · DOI
- Sperling, 2014, The A4 study: stopping AD before symptoms begin?, Sci Transl Med, 6, 228fs13, 10.1126/scitranslmed.3007941 · DOI · Paper page
- American Psychatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders
- Strauss, 2006, A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary
Cited by
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045
Post-Stroke Cognitive Impairment and Dementia
Rost, N. S., Brodtmann, A., Pase, M. P., van Veluw, S. J., Biffi, A., Duering, M., Hinman, J. D., & Dichgans, M. (2022) · Circulation Research · doi:10.1161/circresaha.122.319951 · Cited by 790
Self-citationBubu, O. M., Andrade, A. G., Umasabor-Bubu, O. Q., Hogan, M. M., Turner, A. D., de Leon, M. J., Ogedegbe, G., Ayappa, I., Jean-Louis G, G., Jackson, M. L., et al. (2020) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2019.101250 · Cited by 389
Lantero Rodriguez, J., Karikari, T. K., Suárez-Calvet, M., Troakes, C., King, A., Emersic, A., Aarsland, D., Hye, A., Zetterberg, H., Blennow, K., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02195-x · Cited by 350
Metadata
- Authors
- Pase, M. P., Beiser, A. S., Himali, J. J., Satizabal, C. L., Aparicio, H. J., DeCarli, C., Chêne, G., Dufouil, C., & Seshadri, S.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-05-01
- Volume
- 76
- Issue
- 5
- Pages
- 598
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2920387298
- Cited by
- 204
- References
- 13
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes. https://app.cochat.ai/papers/10.1001/jamaneurol.2018.4666
- The paper
- Pase, M. P., Beiser, A. S., Himali, J. J., Satizabal, C. L., Aparicio, H. J., DeCarli, C., Chêne, G., Dufouil, C., & Seshadri, S. (2019). Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2018.4666
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.